Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
- Preliminary clinical data on G1T28 in combination with chemotherapy in newly diagnosed small-cell lung cancer patients
- Preclinical data on potential best-in-class oral CDK4/6 inhibitor G1T38
RESEARCH TRIANGLE PARK, N.C., April 15, 2016 -- G1 Therapeutics, Inc., a clinical-stage oncology company, announced today that preliminary data from the Phase 1b/2a study of its lead CDK4/6 inhibitor G1T28 as a first-line combination treatment for small-cell lung cancer (SCLC) will be presented in a poster session at the 2016 American Association for Cancer Research (AACR) Annual Meeting, being held April 16 – 20 at the Ernest N. Morial Convention Center in New Orleans, La. In addition, G1 will present preclinical data on its CDK4/6 inhibitor G1T38 in two posters.
Details of the posters to be presented are as follows:
Title: G1T28, a cyclin dependent kinase 4/6 inhibitor, in combination with etoposide and carboplatin for extensive stage small cell lung cancer (ES-SCLC): preliminary results
Abstract Number: CT151
Poster Session: Phase I Clinical Trials 2, Section 13
Date: Wednesday, April 20
Time: 8 a.m. - 12 p.m. CDT
Presenter: Caio Max Rocha Lima, M.D.; Spartanburg Regional Healthcare System
Title: Effects of a CDK 4/6 inhibitor, G1T38, in androgen receptor sensitive and resistant models of castrate resistant prostate cancer
Abstract Number: 2820
Poster Session: Pharmacological Inhibitors of Cyclin-dependent Kinases, Section 6
Date: Tuesday, April 19
Time: 8 a.m. - 12 p.m. CDT
Presenter: Suzanne Wardell, Ph.D.; Assistant Professor, Duke University School of Medicine
Title: G1T38, a novel, oral, potent and selective CDK4/6 inhibitor for the treatment of Rb competent tumors
Abstract Number: 2824
Poster Session: Pharmacological Inhibitors of Cyclin-dependent Kinases, Section 6
Date: Tuesday, April 19
Time: 8 a.m. - 12 p.m. CDT
Presenter: Jay Strum, Ph.D.; Chief Scientific Officer, G1 Therapeutics
Abstracts for each poster and additional information on the meeting can be found on the AACR website: http://www.aacr.org/.
About G1T28
G1T28 is a potential first-in-class combination therapy given intravenously prior to chemotherapy for the treatment of patients with CDK4/6-independent tumors. G1T28 induces a transient cell-cycle arrest of hematopoietic stem and progenitor cells, thereby protecting the bone marrow and immune system from damage by chemotherapy. G1T28 has the potential to significantly improve outcomes for patients with CDK4/6-independent tumors, such as small-cell lung cancer.
G1T28 is being studied in two Phase 1b/2a proof-of-concept trials in patients with small-cell lung cancer: a study in newly diagnosed, treatment-naive patients (NCT02499770), and a study in previously treated patients (NCT02514447).
About G1T38
G1T38 is an oral antineoplastic agent for the treatment of patients with CDK4/6-dependent tumors. In preclinical models, G1T38 enhances anti-tumor activity when combined with therapies that inhibit validated targets, such as the estrogen and androgen receptors. Due to its high selectivity and unique pharmacokinetic and pharmacodynamic profile, G1T38 has the potential to be best-in-class versus other CDK4/6 inhibitors in development.
G1 plans to initiate a Phase 1 clinical trial of G1T38 in the second quarter of 2016.
About G1 Therapeutics, Inc.
G1 Therapeutics is a clinical-stage oncology company developing novel, small-molecule therapies that address significant unmet needs in people with cancer. The company is advancing G1T28, a potential first-in-class drug candidate, and G1T38, a potential best-in-class compound, in multiple oncology indications. G1 is privately held and based in Research Triangle Park, NC.
Visit www.g1therapeutics.com for more information.
Contact: Mark Velleca, MD, PhD G1 Therapeutics 919-213-9838 [email protected] Media: Laura Bagby 6 Degrees Communications 312-448-8098 [email protected]
